Two of the researchers are cofounders and members of the Board of Directors of Holostem Terapie Avanzate, which met all costs of good manufacturing practice production and procedures of transgenic epidermal grafts.
Longer-term follow-up of these four patients will continue, and "controlled trials are needed with a broader range of patients to better understand the potential long-term efficacy of genetically corrected autologous epidermal grafts," said Zurab Siprashvili, PhD, of Stanford (Calif.) University and associates.